查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010043

动物用药品市场：2026-2032年全球市场预测（依产品类型、目标动物、给药途径、疾病类型、最终用户和分销管道划分）

Animal Pharmaceuticals Market by Product Type, Species, Route of Administration, Disease Type, End User, Distribution Channels - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年动物用药品市值为457.4亿美元，预计2026年将成长至499.7亿美元，复合年增长率为9.57%，到2032年将达到867.8亿美元。

主要市场统计数据
基准年 2025 457.4亿美元
预计年份：2026年 499.7亿美元
预测年份 2032 867.8亿美元
复合年增长率 (%) 9.57%

在不断变化的全球健康需求和技术进步的背景下，为动物用药品的策略成长奠定基础。

全球动物用药品产业正处于关键转折点，消费者行为的改变、疾病情势的演变以及技术的突破正在重塑传统的市场动态。新兴市场对优质蛋白质来源的需求不断增长，推动了对畜牧业健康解决方案前所未有的投资；同时，宠物饲养量的增加和预防性护理支出的增长也持续惠及伴侣动物护理行业。此外，人们对通用感染疾病的认识不断提高，迫使相关人员加快研发疫苗和诊断方法，以保护动物和人类的健康。

揭示推动全球兽医市场动物疗法开发和交付模式转移的因素。

随着精准医疗、数位诊断和新型生技药品重塑治疗模式，兽医领域正经历着改变。次单位疫苗和减毒疫苗等先进疫苗平台展现出卓越的安全性和免疫抗原性，迫使生产者重新思考传统方法。同时，远端医疗和基于感测器的监测技术的融合实现了疾病的即时监测，有助于早期疗育，并最终降低治疗成本。

评估美国关税政策在 2025 年对动物用药品市场供应、价格压力和策略重组的多层次影响。

2025年，美国对主要动物用药品进口产品征收多层关税，将给整个供应链带来新的成本压力，迫使製造商重新思考其活性成分的筹资策略。抗生素、荷尔蒙和疫苗佐剂的供应商面临利润空间被压缩的困境，相关人员正在探索替代贸易伙伴关係和近岸外包方案。因此，为了缓解关税造成的价格波动，国内产能正透过资本投资和本地生产合约进行扩张。

我们将对产品、目标动物、给药途径、疾病、最终用户和分销管道等各个方面进行详细分析，以确定策略性细分机会。

详细的細項分析揭示了产品系列中的关键差异，传统类别（如麻醉剂和抗发炎药物）与快速增长的生物製药和标靶驱虫药并存。抗生素仍发挥着至关重要的作用，但其分类日益细分为Fluoroquinolones、大环内酯类、青霉素类、磺胺类药物和四环霉素，反映了治疗应用的细微差别。同时，驱虫策略也在不断发展，力求在频谱驱虫药和特异性体外寄生虫控制药物之间取得疗效平衡；而灭活疫苗、减毒活病毒疫苗和次单位疫苗则在安全性、成本和免疫反应等方面展开竞争。

了解美洲、欧洲、中东和非洲以及亚太地区的趋势，以推动市场扩张并开发个人化的兽医解决方案。

美洲地区的趋势持续受到健全的研究基础设施、清晰的监管流程以及高昂的单隻动物投入的影响。尤其是在北美，大规模畜牧养殖和成熟的伴侣动物市场并存。关键在于，基于区块链的可追溯性和一体化低温运输物流等供应链创新正在提高透明度、减少废弃物并进一步提升市场效率。在拉丁美洲，乳製品和牛肉产业的扩张推动了人们对经济高效的非专利药和社区疫苗接种倡议的日益关注。

动物用药品创新领导者概况：了解其竞争定位、合作趋势及在发展颠覆性策略

动物用药品市场的领导地位由生态系统构成，该系统由行业巨头、高度专业化的中型企业和灵活的生物技术公司组成。老字型大小企业利用其强大的研发开发平臺，推动下一代疫苗、单株抗体和长效注射剂的开发，以应对抗生素抗药性和跨物种通用感染疾病等紧迫挑战。同时，中型企业专注于高利润领域，例如马匹治疗、精准寄生虫控制产品和个人化营养补充剂，从而在细分市场中占据一席之地。

产业领导者面临的策略挑战包括：应对复杂的监管环境、利用技术进步以及优化价值链。

产业领导者应优先将数位健康工具融入其全球商业化策略。投资远距远端医疗平台、感测器驱动的诊断技术和数据分析解决方案，不仅能改善治疗效果，还能打造差异化的服务产品，进而加深客户参与。此外，与生物技术Start-Ups建立策略合作伙伴关係，将加速获取基因编辑和合成生物学等创新平台，确保持续将突破性治疗方法纳入其产品组合。

概述了支持对全球动物用药品市场进行全面分析的严谨的定性和定量方法。

本分析基于严谨的调查方法，该方法融合了定性和定量研究手段。主要研究工作包括对动物用药品生产商的高阶主管、监管专家、供应链经理和学术研究人员进行深入访谈。透过这些对话，我们获得了关于新兴趋势、策略重点和营运挑战的第一手观点。

整合关键见解，引导相关人员走向不断发展的全球动物用药品生态系统的未来。

在本执行摘要中，我们检验了重塑动物用药品产业的许多复杂因素，包括不断变化的消费者需求、监管改革、技术突破以及地缘政治逆风。这些相互交织的因素凸显了相关人员采取灵活策略、利用创新成果以及增强价值链韧性的必要性。市场领导必须追求差异化的价值提案，同时密切注意贸易政策和不断变化的疾病模式所带来的成本压力。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：动物用药品市场：依产品类型划分

  • 麻醉剂
  • 抗发炎药
  • 抗生素
    • Fluoroquinolones
    • 大环内酯类
    • 青霉素
    • 磺胺类药物药物
    • 四环霉素
  • 荷尔蒙和生长调节剂
  • 杀虫剂
    • 驱虫
    • 体外寄生虫控製剂
  • 疫苗
    • 灭活疫苗
    • 减毒活病毒疫苗
    • 次单位疫苗

第九章动物用药品市场：依类型划分

  • 水生动物
  • 鸟类
  • 伴侣动物
    • 猫
    • 狗
    • 马
  • 家畜
    • 牛
    • 家禽
    • 绵羊/山羊
    • 猪
  • 野生动物

第十章：动物用药品市场：依给药途径划分

  • 口服
    • 胶囊
    • 液体
    • 粉末
    • 药片
  • 肠外
  • 外用
    • 奶油
    • 软膏
    • 喷

第十一章动物用药品市场：依疾病类型划分

  • 感染疾病
    • 细菌感染疾病
    • 霉菌感染疾病
    • 寄生虫病
    • 病毒感染疾病
  • 非感染疾病
    • 发炎性疾病
    • 代谢性疾病
    • 营养缺乏
    • 生殖疾病

第十二章：动物用药品市场：依最终用户划分

  • 政府和公共卫生机构
  • 畜牧场及家禽养殖场
  • 宠物饲主
  • 研究机构
  • 动物医院和动物医疗机构

第十三章：动物用药品市场：依通路划分

  • 物理药房
  • 网路药房

第十四章动物用药品市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：动物用药品市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章动物用药品市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国动物用药品市场

第十八章：中国动物用药品市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aurora Pharmaceutical, Inc.
  • Biogenesis Bago SA
  • Biovac Ltd.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Chanelle Pharma
  • China Animal Husbandry Industry Co., Ltd.
  • Dechra Pharmaceuticals PLC
  • ECO Animal Health Group PLC
  • Elanco Animal Health Incorporated
  • Hester Biosciences Limited
  • Huvepharma, Inc.
  • Indian Immunologicals Ltd.
  • Intas Pharmaceuticals Ltd.
  • Laboratorio Drag Pharma Chile Invetec SA
  • Merck & Co., Inc.
  • Neogen Corporation
  • Nippon Zenyaku Kogyo Co., Ltd.
  • Norbrook Group
  • Orion Corporation
  • PetIQ, LLC
  • Phibro Animal Health Corporation
  • Teknofarma Srl
  • Veterinary Pharmaceutical Solutions
  • Vetoquinol Group
  • Vetpharma Animal Health SL by Insud Pharma SLU
  • Virbac SA
  • Zendal Group
  • Zoetis Inc.
Product Code: MRR-434CCDA05128

The Animal Pharmaceuticals Market was valued at USD 45.74 billion in 2025 and is projected to grow to USD 49.97 billion in 2026, with a CAGR of 9.57%, reaching USD 86.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 45.74 billion
Estimated Year [2026] USD 49.97 billion
Forecast Year [2032] USD 86.78 billion
CAGR (%) 9.57%

Laying the Groundwork for Strategic Growth in Animal Pharmaceuticals Amidst Evolving Global Health Demands and Technological Advancements

The global animal pharmaceuticals sector stands at a pivotal juncture as shifting consumer behaviors, evolving disease profiles, and technological breakthroughs converge to reshape traditional market dynamics. Intensifying demand for high-quality protein sources in emerging economies is driving unprecedented investment in livestock health solutions, while companion animal care continues to benefit from rising pet ownership and increasing expenditures on preventive therapies. Furthermore, heightened awareness of zoonotic disease transmission is compelling stakeholders to accelerate research into vaccines and diagnostics that protect both animal and human health.

Amid these trends, regulatory agencies worldwide are streamlining approval pathways for innovative biologics, antimicrobial agents, and point-of-care diagnostics. Public-private partnerships are emerging to combat antimicrobial resistance, while venture capital initiatives are fueling startups to explore gene editing, precision dosing, and digital health platforms. These developments underscore the importance of a multi-faceted strategy that balances the need for rapid product development with stringent safety and efficacy standards.

Accordingly, industry leaders must ground their growth plans in robust market intelligence that captures complex value chains, evolving regulatory frameworks, and shifting epidemiological patterns. By aligning R&D pipelines with emerging customer needs and leveraging cross-sector collaborations, stakeholders can unlock sustainable growth and build resilience against future disruptions.

Uncovering the Forces Driving a Paradigm Shift in Animal Health Treatment Development and Delivery Across Global Veterinary Markets

The animal health landscape is witnessing transformative shifts as precision medicine, digital diagnostics, and novel biologics redefine treatment paradigms. Advanced vaccine platforms, including subunit and attenuated modalities, are demonstrating superior safety profiles and immunogenicity, driving manufacturers to re-evaluate traditional approaches. Meanwhile, the integration of telemedicine and sensor-based monitoring is enabling real-time disease surveillance, facilitating earlier intervention and reducing overall treatment costs.

Moreover, growing concerns around antimicrobial resistance have accelerated interest in alternative therapies such as phage therapy, probiotics, and host-directed immunomodulators. Companies are forging alliances with academic institutions to fast-track these innovations through collaborative research and pooled expertise. In parallel, artificial intelligence and machine learning models are being deployed to optimize dosage regimens and forecast disease outbreaks based on environmental and genetic risk factors.

Consequently, organizations that embrace these disruptive technologies while maintaining a strong focus on regulatory compliance and cost-effectiveness will be best positioned to capture emerging market segments. Building flexible supply networks and investing in agile manufacturing processes will further enable rapid scale-up of production, ensuring timely delivery of next-generation therapies to meet evolving veterinary needs.

Assessing the Layered Effects of 2025 US Tariff Policies on Supply, Pricing Pressure, and Strategic Realignment in the Animal Pharmaceuticals Market

In 2025, the imposition of layered US tariffs on key animal pharmaceutical imports has introduced new cost pressures throughout the supply chain, compelling manufacturers to reassess sourcing strategies for active pharmaceutical ingredients. Suppliers of antibiotics, hormones, and vaccine adjuvants have experienced margin compression, prompting stakeholders to explore alternative trade partnerships and near-shoring options. As a result, domestic production capabilities are being expanded through capacity investments and localized manufacturing agreements to mitigate tariff-induced price volatility.

Furthermore, higher import duties have led to downstream pricing adjustments that influence end-user purchasing behavior, with veterinary clinics and farms increasingly seeking value-based contracts and bundled service offerings. This shift is accelerating the adoption of generic formulations and biosimilars in regions where cost sensitivity remains high. At the same time, premium markets with strong veterinary infrastructure continue to exhibit willingness to pay for innovative biologics and advanced diagnostics.

Accordingly, agile supply chain management and proactive regulatory engagement are paramount. Organizations that secure diversified raw material sources, negotiate long-term procurement agreements, and establish in-country fill-finish capabilities will build resilience against future trade disruptions. Embracing digital supply chain visibility tools and advanced analytics will further empower decision-makers to respond swiftly to shifting tariff landscapes and maintain competitive pricing.

Delving into Product, Species, Administration, Disease, End User, and Channel Dimensions to Reveal Strategic Segmentation Opportunities

Deep segmentation analysis reveals critical differentiation within the product portfolio, where traditional categories such as anesthetics and anti-inflammatory medications coexist with fast-growing biologic vaccines and targeted parasiticides. Antibiotics maintain a prominent role but are increasingly stratified across fluoroquinolones, macrolides, penicillins, sulfonamides, and tetracyclines, reflecting nuanced therapeutic applications. At the same time, parasiticide strategies are evolving to balance efficacy between broad-spectrum anthelmintics and specialized ectoparasiticides, while inactivated vaccines, live attenuated vaccines, and subunit vaccines compete on the basis of safety, cost, and immune response.

Equally important is the species dimension, where treatments for aquatic animals, birds, companion animals such as cats, dogs, and horses, livestock including cattle, poultry, sheep and goats, and swine, as well as wild animal care, present unique pharmacological and delivery challenges. Route of administration further refines market opportunities, as oral solutions in capsules, liquids, powders, and tablets offer convenience but face bioavailability constraints, while parenteral interventions dominate acute care and topical formulations in creams, ointments, and sprays address localized conditions. Disease type segmentation divides interventions between infectious diseases, encompassing bacterial, fungal, parasitic, and viral infections, and non-infectious disorders that range from inflammatory diseases to metabolic, nutritional, and reproductive disorders. End-user profiles complete the landscape, where government and public health bodies, livestock and poultry farms, pet owners, research institutions, and veterinary clinics and hospitals each demonstrate distinct procurement criteria. Finally, the channel dimension highlights the rising influence of online pharmacies alongside established offline pharmacy networks, signaling a shift in distribution strategies.

Mapping Regional Dynamics in Americas, EMEA, and Asia-Pacific to Guide Market Expansion and Tailored Veterinary Health Solutions

Regional dynamics in the Americas continue to be shaped by robust research infrastructure, well-defined regulatory pathways, and high per-animal expenditure, particularly in North America where large-scale livestock operations and sophisticated companion animal markets coexist. Importantly, supply chain innovations such as blockchain-enabled traceability and integrated cold-chain logistics are enhancing transparency and reducing spoilage, further bolstering market efficiency. In Latin America, expanding dairy and beef industries are driving interest in cost-effective generic therapeutics and community vaccination initiatives.

Across Europe, Middle East, and Africa, heterogeneous regulatory frameworks present both challenges and opportunities. EU member states emphasize stringent safety and environmental standards, spurring investment in next-generation biologics and antimicrobial stewardship programs. Meanwhile, Middle Eastern markets are witnessing an uptick in private veterinary services and demand for premium companion animal products. In Africa, emerging economies are prioritizing zoonotic disease control through public health campaigns and donor-funded vaccine distribution, highlighting the need for low-cost, thermostable formulations.

Asia-Pacific stands out for its dual landscape of rapidly modernizing production hubs and diverse disease burdens. Countries with advanced manufacturing capacity, such as Japan and South Korea, continue to lead innovation in precision biologics, while China and India are scaling up generic production to serve domestic and export markets. Southeast Asian nations are increasingly focused on aquaculture health solutions, reflecting the region's significant contribution to global fish protein supply. These varied regional profiles underscore the importance of tailored market entry and product strategies.

Profiling Leading Animal Health Innovators to Understand Competitive Positioning, Collaborative Trends, and Pipeline Disruption Strategies

Market leadership in animal pharmaceuticals is characterized by an ecosystem of industry giants, specialized mid-tier players, and agile biotechnology firms. Established corporations are leveraging their deep R&D pipelines to advance next-generation vaccines, monoclonal antibodies, and long-acting injectables that address pressing challenges such as antimicrobial resistance and cross-species zoonotic threats. Meanwhile, mid-sized companies are carving out niche positions by focusing on high-margin segments such as equine therapeutics, precision parasiticides, and bespoke nutritional supplements.

Collaborative partnerships are reshaping the competitive landscape, as alliances between multinational firms and academic spin-offs accelerate translational research. Licensing agreements for proprietary adjuvants and novel delivery technologies are becoming increasingly common, enabling smaller innovators to scale their solutions through established global networks. In addition, strategic M&A activity highlights a trend toward consolidating complementary capabilities, with acquirers seeking to bolster biologics platforms and digital health offerings. These moves are redefining traditional market hierarchies and setting new benchmarks for value creation.

Strategic Imperatives for Industry Leaders to Navigate Regulatory Complexity, Leverage Technological Advances, and Optimize Value Chains

Industry leaders must prioritize the integration of digital health tools into their global commercialization strategies. Investing in telemedicine platforms, sensor-enabled diagnostics, and data analytics solutions will not only enhance treatment outcomes but also create differentiated service offerings that deepen customer engagement. Furthermore, forging strategic alliances with biotechnology startups can accelerate access to innovative platforms such as gene editing and synthetic biology, ensuring a continuous flow of disruptive therapies into the portfolio.

Regulatory engagement should be elevated from a compliance function to a proactive strategic capability. By participating in policy dialogues, contributing to antimicrobial stewardship guidelines, and advocating for harmonized approval pathways, organizations can shape favorable environments for advanced biologics and novel modalities. Finally, building supply chain resilience through diversified sourcing, in-country manufacturing partnerships, and digital traceability systems will safeguard against future trade disruptions and strengthen market responsiveness.

Outlining Rigorous Qualitative and Quantitative Approaches Underpinning Comprehensive Analysis of the Global Animal Pharmaceuticals Landscape

This analysis is founded on a rigorous research methodology that integrates both qualitative and quantitative approaches. Primary research included in-depth interviews with senior executives at veterinary pharmaceutical manufacturers, regulatory experts, supply chain managers, and academic researchers. These conversations provided firsthand perspectives on emerging trends, strategic priorities, and operational challenges.

Secondary research encompassed an exhaustive review of scientific literature, regulatory filings, patent databases, and industry publications. Market dynamics were further validated through proprietary data sets and trade statistics, while competitive landscapes were mapped using detailed product registries and company disclosures. All data points underwent cross-verification to ensure accuracy and relevance, and insights were synthesized through collaborative workshops with subject-matter experts. This robust methodology underpins the credibility and depth of our findings.

Synthesizing Critical Findings to Chart a Path Forward for Stakeholders in the Evolving Global Veterinary Pharmaceuticals Ecosystem

Throughout this executive summary, we have navigated the intricate forces reshaping the animal pharmaceuticals industry, from shifting consumer demands and regulatory reforms to technological breakthroughs and geopolitical headwinds. The convergence of these factors underscores the necessity for stakeholders to adopt agile strategies, harness emerging innovations, and strengthen supply chain resilience. As market leaders pursue differentiated value propositions, they must remain vigilant to cost pressures introduced by trade policies and evolving disease patterns.

Looking ahead, sustained growth will depend on the ability to balance investment across core segments such as antibiotics, vaccines, and parasiticides while exploring frontier areas including precision biologics, digital health, and alternative therapeutics. By embedding a culture of continuous innovation and proactive collaboration, organizations can position themselves to meet the complex health needs of diverse animal populations and drive sustainable value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Pharmaceuticals Market, by Product Type

  • 8.1. Anesthetics
  • 8.2. Anti-Inflammatory Medications
  • 8.3. Antibiotics
    • 8.3.1. Fluoroquinolones
    • 8.3.2. Macrolides
    • 8.3.3. Penicillins
    • 8.3.4. Sulfonamides
    • 8.3.5. Tetracyclines
  • 8.4. Hormones & Growth Regulators
  • 8.5. Parasiticides
    • 8.5.1. Anthelmintics
    • 8.5.2. Ectoparasiticides
  • 8.6. Vaccines
    • 8.6.1. Inactivated Vaccines
    • 8.6.2. Live Attenuated Vaccines
    • 8.6.3. Subunit Vaccines

9. Animal Pharmaceuticals Market, by Species

  • 9.1. Aquatic Animals
  • 9.2. Birds
  • 9.3. Companion Animals
    • 9.3.1. Cats
    • 9.3.2. Dogs
    • 9.3.3. Horses
  • 9.4. Livestock Animals
    • 9.4.1. Cattle
    • 9.4.2. Poultry
    • 9.4.3. Sheep & Goats
    • 9.4.4. Swine
  • 9.5. Wild Animals

10. Animal Pharmaceuticals Market, by Route of Administration

  • 10.1. Oral
    • 10.1.1. Capsules
    • 10.1.2. Liquid solutions
    • 10.1.3. Powders
    • 10.1.4. Tablets
  • 10.2. Parenteral
  • 10.3. Topical
    • 10.3.1. Creams
    • 10.3.2. Ointments
    • 10.3.3. Sprays

11. Animal Pharmaceuticals Market, by Disease Type

  • 11.1. Infectious Diseases
    • 11.1.1. Bacterial Infections
    • 11.1.2. Fungal Infections
    • 11.1.3. Parasitic Infestations
    • 11.1.4. Viral Infections
  • 11.2. Non-Infectious Diseases
    • 11.2.1. Inflammatory Diseases
    • 11.2.2. Metabolic Disorders
    • 11.2.3. Nutritional Deficiencies
    • 11.2.4. Reproductive Disorders

12. Animal Pharmaceuticals Market, by End User

  • 12.1. Government & Public Health Organizations
  • 12.2. Livestock Farms & Poultry Farms
  • 12.3. Pet Owners
  • 12.4. Research Institutions
  • 12.5. Veterinary Clinics & Hospitals

13. Animal Pharmaceuticals Market, by Distribution Channels

  • 13.1. Offline Pharmacies
  • 13.2. Online Pharmacies

14. Animal Pharmaceuticals Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Animal Pharmaceuticals Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Animal Pharmaceuticals Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Animal Pharmaceuticals Market

18. China Animal Pharmaceuticals Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Aurora Pharmaceutical, Inc.
  • 19.6. Biogenesis Bago S.A.
  • 19.7. Biovac Ltd.
  • 19.8. Boehringer Ingelheim International GmbH
  • 19.9. Ceva Sante Animale
  • 19.10. Chanelle Pharma
  • 19.11. China Animal Husbandry Industry Co., Ltd.
  • 19.12. Dechra Pharmaceuticals PLC
  • 19.13. ECO Animal Health Group PLC
  • 19.14. Elanco Animal Health Incorporated
  • 19.15. Hester Biosciences Limited
  • 19.16. Huvepharma, Inc.
  • 19.17. Indian Immunologicals Ltd.
  • 19.18. Intas Pharmaceuticals Ltd.
  • 19.19. Laboratorio Drag Pharma Chile Invetec S.A.
  • 19.20. Merck & Co., Inc.
  • 19.21. Neogen Corporation
  • 19.22. Nippon Zenyaku Kogyo Co., Ltd.
  • 19.23. Norbrook Group
  • 19.24. Orion Corporation
  • 19.25. PetIQ, LLC
  • 19.26. Phibro Animal Health Corporation
  • 19.27. Teknofarma S.r.l.
  • 19.28. Veterinary Pharmaceutical Solutions
  • 19.29. Vetoquinol Group
  • 19.30. Vetpharma Animal Health S.L. by Insud Pharma S.L.U.
  • 19.31. Virbac S.A.
  • 19.32. Zendal Group
  • 19.33. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL PHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORMONES & GROWTH REGULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORMONES & GROWTH REGULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORMONES & GROWTH REGULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY AQUATIC ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY AQUATIC ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY AQUATIC ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY WILD ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY WILD ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY WILD ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUID SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUID SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFESTATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFESTATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITIC INFESTATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL DEFICIENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL DEFICIENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL DEFICIENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK FARMS & POULTRY FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK FARMS & POULTRY FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK FARMS & POULTRY FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS & HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS & HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS & HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OFFLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY OFFLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPECIES, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY NON-INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2032 (USD MILLION)
  • TABLE 311. GLOBAL ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 312. ASEAN ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 313. ASEAN ANIMAL PHARMACEUTICALS MARKET SI